

Thalidomide-O-C4-COOH Biochemical

Thalidomide-O-C4-COOH

CATALOG #
AAA228183


PRODUCT SYNONYMS

Thalidomide-O-C4-COOH; Thalidomide-O-C4-COOH biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2169266-67-3
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Palmitic acid-13C16 sodium, CAS 2483736-17-8



Structure
Palmitic acid-13C16 sodium, CAS 2483736-17-8

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-O-C4-COOH biochemical	Thalidomide-O-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	- Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. - Harada H, et al. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. Anticancer Res. 2002 Sep-Oct;22(5):2587-90.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

